Cipla has announced its partnership with the Premier Medical Corporation Private Limited for commercialisation of the rapid antigen test kits for Covid-19 in India. The company will commence supply from this week.
This is Cipla's second launch in the diagnostics space after Elifast ELISA Test Kit.
Cipla with this collaboration will be able to market and distribute the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen, to be manufactured by Premier Medical Corporation Private Limited.
The test is a rapid point-of-care nasopharyngeal swab test that directly detects the presence or absence of coronavirus antigen in the patient's body, generating results within 15-20 minutes.
ICMR has authorised labs that can conduct rapid antigen testing. The test will be sold under the brand name 'CIPtest' in India.
ICMR approved and verified - CIPtest is a reliable high-performing kit.
Also Read: Centre directs states to be ready for 'adverse' effects of Covid-19 vaccination
The kit is found to have specificity and sensitivity of 98.09 per cent and up to 75 per cent respectively. The test is not only rapid with a quick turn-around time but also enables easy interpretation of results without the need for any additional instrument.
Cipla's expansive distribution network will help in ensuring the supply of kits across the country.